ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, announced today that the Company is moving its research laboratories to Genopole, a leading biocluster dedicated to biotechnology and research in genomics and genetics. The new laboratories brings Enterome closer to its existing and potential new partners and provides opportunities to extend its scientific expertise and network to develop its business (...)
Malakoff – FRANCE, August 29th, 2017 – THERACLION (Alternext, FR0010120402 – ALTHE, PEA PME eligible), a company specialized in leading-edge medical equipment for echotherapy, today announces the results published in the « Radiology » journal on Graves’ disease treatment by echotherapy using Echopulse. The study is entitled : “Single-Session High-Intensity Focused Ultrasound Treatment for Persistent or Relapsed Graves’ Disease : Preliminary Experience in a Prospective Study” and is available (...)
Evry, France, 11 July 2017, 8h00 - IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, today announced its sales for the first half of 2017. Strong growth in genomics services for clinical research and microbiology
Leaders of Sustainable Biofuels welcome French company Global Bioenergies as new member : “Significant increase in interest in advanced biofuels evident as the discussions on future EU policy are soon entering decision-making time” Leaders of Sustainable Biofuels coalition welcomes French company Global Bioenergies as new member of the coalition promoting advanced biofuels as fast track solution to cut transport emissions. Global Bioenergies develops innovative processes converting a broad (...)
Theraclion (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announce that the first patients were treated in the U.S. pivotal clinical trial to evaluate the safety and efficacy of Echopulse® echotherapy as a non-invasive treatment of breast fibroadenomas (BFAs).
Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised €1,5M from CapDecisif Management. Acticor Biotech had already secured €1,4M in the first closing, which brings the total amount invested to €2,9M.
Laboratoire Cerba and METAFORA biosystems are proud to announce the availability of the innovative test METAglut1 in routine biology to help diagnose the GLUT1 deficiency syndrome (GLUT1-DS)
Global Bioenergies (Alternext Paris : ALGBE) has finalized the acquisition of Syngip B.V. at the close of its extraordinary shareholders’ meeting today. Syngip B.V. is a start-up based in the Netherlands that specializes in converting third-generation resources into fuels and materials.
Butagaz, a leading French brand distributing gas in bottles and tanks, continues its innovation drive to contribute to meeting France’s greenhouse gas emissions reduction target. The partnership with Global Bioenergies aims at incorporating batches of bio-isobutene produced at Global Bioenergies’ demo plant as early as 2017 and then by the first commercial bio-isobutene plant once built in (...)
Capital Finance International (CFI), a print journal and online resource reporting on business, economics, and finance and Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that the CFI.co judges have conferred on Pharnext its Best Life-Sciences IPO France 2016 (...)